Jing Medicine Technology
Pudong
About Jing Medicine Technology
Jing Medicine Technology (Shanghai) Ltd. is an innovative pharmaceuticals enterprise, located within ShanghaiTech University in Shanghai Pudong New Area. Established in 2017, with about $20M in Series A financing, the mission of the company is to commercialize some of the life science research at ShanghaiTech University. Jing Medicine is committed to the development of therapeutic monoclonal antibody and small molecule drugs. Several research projects currently in the preclinical stage own their rights of intellectual property. A number of projects have formed domestic and international collaboration. The core R&D and management team members are composed of senior executives and scientists from the United States and China, with extensive experience in world-class biotech and pharmaceutical companies. The company is a foreign joint venture, and the investors have strong background in pharmaceutical industry and excellent experience in the biotech and pharmaceutical investment field. The series A investors include Shanghai Alliance Investment Ltd. (SAIL), WuXi AppTec (Shanghai) Co., Ltd., ZL China Holding Two (ZAI Lab) and Shanghai Cenova Xinghe Venture Capital Center, L.P. OUR VALUE
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Last round: Series Unknown (Jan 2021)
- Website: jingmedicine.com
- Phone: 021-68816670
Industries & Categories
Oncology, Pharmaceutical
Canonical: https://fsome.com/organization/jing-medicine-technology-2615769 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.